List of Excipients in Branded Drug SODIUM NITROPRUSSIDE

Generic Drugs Containing SODIUM NITROPRUSSIDE

Company	Ingredient	NDC	Excipient
Hainan Poly Pharm Co Ltd	sodium nitroprusside	14335-131	WATER
Hainan Poly Pharm Co Ltd	sodium nitroprusside	14335-134	SODIUM CHLORIDE
Hainan Poly Pharm Co Ltd	sodium nitroprusside	14335-134	WATER
Nexus Pharmaceuticals LLC	sodium nitroprusside	14789-012	WATER
Akorn	sodium nitroprusside	17478-014	WATER
Sagent Pharmaceuticals	sodium nitroprusside	25021-310	WATER

What are the Most Frequently-Used Excipients in SODIUM NITROPRUSSIDE?

# Of NDCs	Excipient
1	SODIUM CHLORIDE
20	WATER

Sodium Nitroprusside Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Sodium nitroprusside is an established intravenous vasodilator with limited molecule-level patent value and greater commercial potential in formulation, packaging, stability, and hospital-use improvements. The strongest product opportunities are ready-to-use presentations, improved light protection, minimized preparation steps, and differentiated containers that preserve potency during storage and infusion.

The active pharmaceutical ingredient is highly sensitive to light and can generate cyanide-related toxic metabolites during metabolism. Excipients and packaging must therefore support chemical stability, dose accuracy, compatibility with infusion systems, and controlled clinical use. A low-complexity, preservative-free formulation with validated light protection is the most commercially defensible development strategy.

What is sodium nitroprusside used for?

Sodium nitroprusside is an intravenous nitric oxide donor used for rapid reduction of blood pressure and controlled hypotension. FDA labeling covers hypertensive crises, acute congestive heart failure, and controlled hypotension during surgery. It has an immediate onset and a short duration of action, making it suitable for intensive-care and operating-room titration.[1]

Attribute	Sodium nitroprusside
Active ingredient	Sodium nitroprusside
Pharmacologic class	Direct arterial and venous vasodilator
Route	Intravenous infusion
Typical presentation	Concentrated solution or premixed infusion
Key chemical risk	Light degradation and cyanide generation
Primary care setting	ICU, emergency department, operating room
FDA pathway for legacy products	NDA and abbreviated generic pathways
Biosimilar relevance	None; this is a small-molecule drug
Main formulation challenge	Maintaining potency during dilution, storage, and infusion

The drug is generally administered by continuous infusion through a calibrated pump. The label requires careful titration and monitoring because excessive blood-pressure reduction and thiocyanate or cyanide toxicity can occur.[1]

What excipients are used in sodium nitroprusside products?

The principal commercial excipient strategy is an aqueous vehicle with either dextrose or another validated infusion-compatible medium. The excipient system is intentionally simple because additional ingredients can create compatibility, toxicity, or regulatory risks.

Dextrose-containing formulations

Traditional sodium nitroprusside products are supplied as a concentrated sterile solution that is diluted in 5% dextrose injection before administration. Dextrose has several commercial advantages:

• It is a well-established parenteral vehicle.
• It has broad clinical familiarity.
• It supports compatibility with common infusion protocols.
• It avoids the need to introduce novel stabilizers into a highly reactive drug system.

The historical labeling for Nitropress instructed dilution in 5% dextrose injection and protection from light.[1] Product developers should not assume that a formulation validated in dextrose will have equivalent stability in sodium chloride or balanced electrolyte solutions.

Sodium chloride and premixed formulations

A ready-to-use product may use 0.9% sodium chloride, 5% dextrose, or another infusion vehicle if the final formulation demonstrates acceptable potency, impurity levels, pH, particulate control, container compatibility, and in-use stability.

The vehicle choice affects:

• Sodium load.
• Osmolality.
• Compatibility with concurrent infusions.
• Hospital preference.
• Labeling and administration instructions.
• Container and tubing adsorption.
• Stability after opening or connection to an infusion set.

A sodium chloride presentation could have commercial value in hospitals that standardize most continuous infusions in saline. It would require a complete stability and compatibility package rather than a simple substitution of the diluent.

pH modifiers and buffering agents

A buffer may improve pH control, but buffering is not automatically beneficial. Sodium nitroprusside is chemically sensitive, and the selected pH range can affect degradation pathways, impurity formation, and container interaction.

Any citrate, phosphate, acetate, or other buffer system would require:

1. Forced-degradation studies.
2. Long-term and accelerated stability testing.
3. Compatibility studies with infusion bags and tubing.
4. Assessment of cyanide-related degradation products.
5. Extractables and leachables testing.
6. Clinical justification if the formulation materially changes exposure or administration.

A buffer-free formulation is generally preferable when the existing product can meet specifications without one.

Preservatives, antioxidants, and chelators

Preservatives have limited value in a single-use or single-patient infusion product and may create safety concerns in critically ill patients. Antioxidants and chelators could theoretically reduce specific degradation pathways, but their use would require evidence that they do not alter drug activity, impurity profiles, or infusion compatibility.

Commercial developers should avoid adding excipients solely to create formulation differentiation. In this product category, an unnecessary excipient can increase regulatory burden without improving clinical value.

What formulation patents protect sodium nitroprusside?

Sodium nitroprusside has limited remaining composition-of-matter value because the active ingredient and its clinical use are long established. Current product differentiation is more likely to rely on formulation, container, process, and delivery-system claims than on the molecule itself.

IP category	Commercial relevance	Likely strength
Sodium nitroprusside molecule	Historical only	Low for new products
Basic intravenous solution	Broad prior art	Low to moderate
Light-protective packaging	Product differentiation	Moderate if technically specific
Ready-to-use infusion bag	Commercial and operational value	Moderate
Stability-enhancing formulation	Potentially valuable	Moderate to high if unexpected
Specialized syringe or cartridge	Device and combination-product value	Moderate
Manufacturing process	Can protect quality and yield	Moderate
Method of treating hypertension	Generally crowded and old	Low
New dosing or monitoring method	Possible regulatory value	Case-specific

Patent protection may exist for particular product presentations, manufacturing processes, packaging systems, or drug-device combinations. A freedom-to-operate review should examine U.S. patents, pending applications, international equivalents, and patent-term status before investment.

Orange Book status and listed patents

The Orange Book is relevant to approved prescription drug products and patent certifications under the abbreviated new drug application process.[2] Sodium nitroprusside products are legacy small-molecule products, and commercial entry generally depends on whether a proposed product qualifies as therapeutically equivalent to a listed reference product.

No biosimilar pathway applies. A generic sponsor would ordinarily evaluate:

• Reference-listed drug status.
• Approved dosage form and strength.
• Pharmaceutical equivalence.
• Bioequivalence or waiver eligibility.
• Patent listings and regulatory exclusivity.
• Labeling differences.
• Manufacturing and container requirements.

Because patent listings and regulatory status can change, a transaction or launch decision should rely on the current FDA Orange Book and FDA approval records rather than historical product literature.[2,3]

When does sodium nitroprusside lose exclusivity?

The active ingredient’s practical market exclusivity expired decades ago. Sodium nitroprusside has no modern biologic exclusivity period and is not protected by a current new-molecule exclusivity framework.

Exclusivity type	Relevance to sodium nitroprusside
New chemical entity exclusivity	Expired or not relevant to current entry
Orphan-drug exclusivity	Not generally applicable
Pediatric exclusivity	No material current role identified
Biologic reference-product exclusivity	Not applicable
Formulation patent term	Depends on product-specific patents
Method-of-use patent term	Depends on listed or unlisted claims
Regulatory exclusivity for a new product	Possible only for a qualifying new approval

The commercial barrier is therefore not basic exclusivity. It is the ability to obtain approval, maintain sterile manufacturing, demonstrate stability, secure hospital contracts, and provide reliable supply.

What generic entry risks exist for sodium nitroprusside?

Generic entry risk is structurally high because the molecule is old, the clinical use is established, and multiple formulation approaches are possible. The principal barriers are technical and operational rather than patent-based.

Paragraph IV challenges

A Paragraph IV certification may be relevant if a proposed generic challenges an unexpired listed patent associated with a reference product. The commercial importance depends on:

• Whether the patent is listed in the Orange Book.
• Whether the patent claims the drug, formulation, method of use, or delivery system.
• Whether the proposed label requires the patented use.
• Whether litigation triggers a 30-month stay.
• Whether the generic sponsor seeks a skinny label.

For an old injectable drug, the most relevant claims would likely concern formulation, container closure, stability, or administration rather than the sodium nitroprusside molecule.

Manufacturing and quality risks

Sterile injectable products carry substantial execution risk. Generic and reformulated products must control:

• Sterility assurance.
• Endotoxin levels.
• Visible and subvisible particulates.
• Container closure integrity.
• Drug concentration uniformity.
• Light exposure during filling and distribution.
• Degradation during infusion.
• Compatibility with common administration sets.

A sponsor with a validated sterile injectable platform may have a stronger competitive position than a sponsor with only low-cost API access.

What formulations are commercially protected or differentiated?

The most attractive formulation concepts are those that reduce hospital preparation and exposure to light without introducing unnecessary excipients.

Ready-to-use infusion bags

Ready-to-use bags can eliminate dilution errors, reduce pharmacy preparation time, and improve dose standardization. Their value is strongest in high-acuity settings where rapid initiation matters.

Commercial design variables include:

• Standardized concentrations.
• Multiple bag sizes.
• Low-sorption bag materials.
• Secondary overwraps.
• Light-resistant primary containers.
• Tamper-evident packaging.
• Bar-code integration.
• Extended refrigerated or room-temperature shelf life.

A ready-to-use product may require a 505(b)(2) application if it differs materially from the reference product, although some products may qualify for an ANDA depending on pharmaceutical equivalence and FDA requirements.[3]

Prefilled syringes

A prefilled syringe could target operating rooms, emergency departments, and procedural settings. Its advantages include dose portability and reduced preparation time. The limitations are short treatment durations, concentration flexibility, syringe-material compatibility, and the need to ensure accurate pump delivery.

The product would likely be more defensible if combined with:

• A light-resistant syringe system.
• A calibrated delivery device.
• A standardized concentration.
• Electronic medication-management compatibility.
• Validated in-use stability.

Light-protective packaging

Light protection is a core product requirement rather than a minor packaging preference. Potential approaches include:

• Amber or opaque containers.
• Light-resistant overwraps.
• Secondary foil packaging.
• Light-protective administration sleeves.
• Integrated overwraps that remain in place during infusion.
• Packaging that limits exposure during pharmacy preparation.

Packaging claims are most valuable when tied to demonstrated stability performance under defined light conditions. A generic claim covering any opaque container would face substantial prior-art risk.

Low-sorption container systems

The formulation should be evaluated against common infusion bag and tubing materials. Adsorption or absorption may reduce delivered dose, particularly at low concentrations and during long infusion periods.

Potentially valuable technical data include:

• Drug recovery after storage.
• Drug recovery after passage through tubing.
• Compatibility with pump systems.
• Stability in PVC and non-PVC administration sets.
• Delivered-dose accuracy at clinically relevant flow rates.

How strong is the patent estate for sodium nitroprusside?

The patent estate is likely weak at the molecule level and stronger only where a sponsor develops a technically differentiated product.

Estate component	Assessment
Composition of matter	Weak or expired
Conventional diluted solution	Crowded
Standard dextrose formulation	Limited exclusivity potential
Ready-to-use presentation	Moderate opportunity
Light-stable container system	Moderate opportunity
Novel delivery device	Moderate opportunity
New stability technology	Potentially strong if unexpected
Manufacturing process	Useful secondary protection
Method of use	Generally limited for established indications

A robust filing strategy would use several claim layers:

1. Composition claims covering concentration and excipient ranges.
2. Container claims covering light transmission and materials.
3. Method claims covering storage and administration.
4. Manufacturing claims covering order of addition, filling, and light control.
5. Combination claims covering the drug, container, tubing, and infusion device.

The strongest claims would be supported by comparative data showing improved potency retention, lower impurity formation, or better delivered-dose accuracy than conventional products.

What FDA regulatory pathway applies to a new sodium nitroprusside product?

The regulatory pathway depends on how closely the product matches an approved reference product.

ANDA pathway

An ANDA may be appropriate for a product that matches the reference product in active ingredient, dosage form, strength, route, and other required characteristics. Injectable products may require detailed pharmaceutical equivalence and quality data even when conventional bioequivalence studies are limited or unnecessary.[3]

505(b)(2) pathway

A 505(b)(2) application may be more suitable for:

• A ready-to-use formulation with a different concentration.
• A new diluent or container system.
• A prefilled syringe.
• A new route or administration method.
• A product with new stability or usability claims.
• A formulation that relies partly on published literature or FDA findings for the active ingredient.

The 505(b)(2) route can support product differentiation but may expose the sponsor to listed-patent certifications and potential litigation.

Which companies are positioned to challenge or compete with sodium nitroprusside products?

Competition is likely to come from three groups:

Generic injectable manufacturers

These companies compete on:

• Unit price.
• Manufacturing reliability.
• Contracting scale.
• Hospital formulary access.
• Shortage response.
• Supply-chain continuity.

Hospital-focused specialty pharmaceutical companies

These companies can differentiate through ready-to-use bags, prefilled syringes, standardized concentrations, and pharmacy workflow products. Their advantage is commercial execution rather than molecule ownership.

Contract manufacturing and CDMO platforms

A CDMO with sterile filling, light-controlled production, and parenteral packaging capabilities may enable rapid market entry. The main commercial risk is dependence on a third party for critical quality attributes and supply continuity.

What licensing deals could create value?

The most relevant licensing opportunities are unlikely to involve the sodium nitroprusside molecule. They are more likely to involve:

• Sterile ready-to-use bag technology.
• Light-protective packaging.
• Prefilled syringe systems.
• Low-sorption tubing or container materials.
• Hospital medication-preparation platforms.
• International distribution rights.
• Manufacturing rights in regions with limited injectable supply.

A license should distinguish between product-specific rights and platform rights. A platform license that covers multiple ICU injectables may have greater value than a sodium nitroprusside-only agreement, provided the patent claims and regulatory data transfer are adequate.

Key diligence points include:

• Ownership of formulation and packaging patents.
• Patent expiration and geographic coverage.
• Regulatory filing ownership.
• Transferability of stability data.
• Existing supply agreements.
• Manufacturing-site qualification.
• Change-control obligations.
• Rights to improvements and follow-on products.

What patent litigation and settlement risks affect sodium nitroprusside?

Patent litigation risk is likely lower than for recently approved specialty drugs, but it is not zero. Litigation could arise from:

• A ready-to-use formulation patent.
• A prefilled syringe or delivery-device patent.
• A light-protection system.
• A manufacturing-process patent.
• A listed method-of-use patent.
• Trade-secret disputes involving sterile manufacturing or stability methods.

Settlement agreements could include delayed launch, authorized generic arrangements, manufacturing licenses, or geographic restrictions. Any diligence review should search federal court records, FDA patent listings, and assignment databases for the specific reference product and proposed formulation.[2,4]

What are the commercial opportunities in sodium nitroprusside?

The most credible opportunities are workflow and supply-chain products.

Opportunity	Customer benefit	Commercial attractiveness
Ready-to-use infusion bags	Reduces pharmacy preparation	High
Standardized concentrations	Simplifies pump programming	Moderate to high
Light-protective administration kit	Reduces handling risk	Moderate
Prefilled syringe	Speeds procedural use	Moderate
Extended shelf life	Reduces inventory loss	High if validated
Saline-based presentation	Fits hospital protocols	Moderate
Low-sorption tubing package	Improves delivered-dose control	Moderate
Dual-source manufacturing	Reduces shortage exposure	High
International supply	Addresses local availability gaps	Market-specific

Revenue exposure

Sodium nitroprusside revenue is exposed to generic price erosion, hospital purchasing consolidation, and intermittent injectable shortages. A product with no meaningful formulation or supply advantage may compete mainly on price.

Revenue durability improves when the product has:

• A differentiated presentation.
• Reliable availability.
• Strong pharmacy-service economics.
• Fewer preparation steps.
• Lower medication-error risk.
• Contracting advantages.
• A broader ICU injectable portfolio.

A sponsor should evaluate the product as part of a hospital injectable platform rather than as a standalone molecule.

How does sodium nitroprusside compare with competing antihypertensive injectables?

Sodium nitroprusside competes with drugs such as nicardipine, clevidipine, nitroglycerin, labetalol, and hydralazine. The alternatives differ in onset, titratability, formulation complexity, monitoring requirements, and hospital purchasing dynamics.

Product	Main formulation issue	Commercial comparison
Sodium nitroprusside	Light sensitivity and cyanide monitoring	Low molecule exclusivity; formulation opportunity
Nicardipine	Dilution and infusion compatibility	Strong ICU generic competition
Clevidipine	Lipid emulsion and specialized presentation	Greater formulation complexity
Nitroglycerin	Adsorption and container compatibility	Established infusion market
Labetalol	Concentration and compatibility	Broad generic availability
Hydralazine	Intermittent dosing and variability	Less suited to continuous titration

Sodium nitroprusside can remain competitive where rapid, predictable titration is required. Its disadvantages include monitoring burden and handling requirements. A ready-to-use, light-protected product could address some operational disadvantages without changing the active ingredient.

What geographic coverage matters for sodium nitroprusside patents?

Patent value depends on the market because the active ingredient is old and the commercial opportunity is presentation-specific.

Priority jurisdictions include:

• United States, because of FDA approval and hospital purchasing scale.
• European Union, because of national tender markets.
• United Kingdom, because of separate regulatory and procurement processes.
• Japan, because of stringent injectable quality requirements.
• China, because of hospital volume and local manufacturing competition.
• India, because of generic production and export capability.
• Latin America and the Middle East, where supply reliability can influence procurement.

A global filing program should prioritize jurisdictions with meaningful injectable demand and enforceable patent systems. Packaging and device claims may have different patentability and enforcement profiles from formulation claims.

Key Takeaways

• Sodium nitroprusside has little remaining molecule-level exclusivity value.
• The main commercial opportunity is a differentiated intravenous presentation.
• Ready-to-use bags, prefilled syringes, and light-protective packaging offer the clearest product concepts.
• Dextrose remains the established vehicle, but saline-based products may address hospital protocol preferences if stability is demonstrated.
• Preservatives, buffers, antioxidants, and chelators should not be added without a specific stability or usability benefit.
• Patent strength is likely to come from formulation, packaging, delivery-system, and manufacturing claims.
• Paragraph IV risk depends on any unexpired product-specific patents listed for the selected reference product.
• No biosimilar pathway applies.
• Reliable sterile manufacturing and supply continuity may create more commercial value than broad molecule claims.
• A platform strategy covering multiple ICU injectables may produce better returns than a sodium nitroprusside-only investment.

FAQs

Can sodium nitroprusside be formulated in normal saline?

It may be possible, but equivalence to a dextrose-based formulation cannot be assumed. The sponsor must establish chemical stability, impurity control, compatibility, container performance, and in-use stability in 0.9% sodium chloride.

Does sodium nitroprusside require protection from light during infusion?

Yes. FDA labeling for established products requires light protection because sodium nitroprusside is light sensitive.[1] A commercial product should validate protection during storage, preparation, transport, and administration.

Is sodium nitroprusside a good candidate for a prefilled syringe?

It can be, particularly for operating-room and emergency-use settings. The product must address syringe-material compatibility, concentration flexibility, light protection, pump accuracy, and in-use stability.

Can a new sodium nitroprusside formulation receive new patent protection?

Potentially. New claims may cover a specific excipient range, concentration, container, light-transmission limit, delivery device, stability profile, or manufacturing process. Broad claims to the old active ingredient are unlikely to provide meaningful protection.

Does sodium nitroprusside have biosimilar competition?

No. Sodium nitroprusside is a chemically synthesized small molecule. Competition occurs through generic-drug and reformulated injectable pathways, not biosimilar approval.

References

1. U.S. Food and Drug Administration. (n.d.). Nitropress (sodium nitroprusside) injection prescribing information. FDA-approved labeling.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process and generic drug standards. https://www.fda.gov/drugs/generic-drugs

4. U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov/